+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "RSV F Vaccine"

Global Respiratory Syncytial Virus Market Size and Epidemiology (8MM), By Drug Type (Synagis, Other), By Dosage Form (Oral, Other), By Treatment Type (Immune prophylaxis, Other), By Distribution Channel (Clinics, Other) -Estimation & Forecast - Product Thumbnail Image

Global Respiratory Syncytial Virus Market Size and Epidemiology (8MM), By Drug Type (Synagis, Other), By Dosage Form (Oral, Other), By Treatment Type (Immune prophylaxis, Other), By Distribution Channel (Clinics, Other) -Estimation & Forecast

  • Report
  • June 2021
  • 675 Pages
  • Global
From
  • 1 Results (Page 1 of 1)
Loading Indicator

The RSV F Vaccine is a vaccine used to protect against respiratory syncytial virus (RSV) infection. RSV is a common virus that can cause severe respiratory illness in infants and young children. The RSV F Vaccine is a recombinant subunit vaccine, which means it is made from a protein that is found on the surface of the virus. It is approved for use in infants and young children in the United States and other countries. The RSV F Vaccine market is a growing segment of the global vaccine market. It is estimated that the RSV F Vaccine market will reach $1.2 billion by 2025. The market is driven by increasing awareness of the importance of immunization, the availability of new vaccines, and the increasing prevalence of RSV infection. The RSV F Vaccine market is dominated by a few large pharmaceutical companies, including GlaxoSmithKline, Merck, and Pfizer. Other companies in the market include Sanofi Pasteur, AstraZeneca, and Novavax. Show Less Read more